Northwest Biotherapeutics (NWBO) Profit After Tax Growth (3y) (2013 - 2026)

Northwest Biotherapeutics (NWBO) Profit After Tax Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.53%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -27.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 70.25%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Northwest Biotherapeutics 272.75 Mn 270.97 Mn - 35.16%

Historic Data

Download Data
DateValue
Mar 31, 2026 35.16%
Dec 31, 2025 27.01%
Sep 30, 2025 6.53%
Jun 30, 2025 13.52%
Mar 31, 2025 -14.35%
Dec 31, 2024 -30.28%
Sep 30, 2024 -34.36%
Jun 30, 2024 -82.23%
Mar 31, 2024 -64.38%
Dec 31, 2023 60.44%
Sep 30, 2023 50.51%
Jun 30, 2023 37.10%
Mar 31, 2023 -82.28%
Dec 31, 2022 -84.92%
Sep 30, 2022 -72.76%
Jun 30, 2022 -416.10%
Mar 31, 2022 12.12%
Dec 31, 2021 122.43%
Sep 30, 2021 60.45%
Jun 30, 2021 29.63%